ADMA Biologics Faces Securities Fraud Class Action Over Alleged Misconduct

The complaint alleges that ADMA Biologics violated the Securities Exchange Act of 1934 by issuing false and materially misleading statements. According to the filing, the company engaged in an undisclosed related party transaction and employed channel stuffing tactics to artificially bolster its reported revenue. Furthermore, the lawsuit contends that the firm failed to maintain adequate internal controls to ensure accurate financial reporting.

Shareholders who suffered financial losses during the specified class period have until August 10, 2026, to seek appointment as lead plaintiff. Attorneys Brian Schall and David Schwartz are overseeing the case, emphasizing that investors do not need to act as lead plaintiffs to remain eligible for a potential recovery. While the class has not yet been certified, those who choose not to participate may still remain absent class members, though they will not be represented by counsel until formal certification occurs.